| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 7,530 | 94,590 | 70,430 | 55,830 | 26,870 |
| Sales Growth | -92.04% | +34.30% | +26.15% | +107.78% | -14.70% |
| Net Income | -526,240 | -388,960 | -215,310 | -127,290 | -121,690 |
| Net Income Growth | -35.29% | -80.65% | -69.15% | -4.60% | -14.49% |
Cytokinetics (CYTK)
45.51 -0.49 (-1.07%) 09:44 ET [NASDAQ]
45.33 x 5 45.56 x 101
Realtime by (Cboe BZX)
45.33 x 5 45.56 x 101
Realtime 45.50 -0.50 (-1.09%) 06:50 ET
for Mon, Mar 3rd, 2025
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy.
Fiscal Year End Date: 12/31